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Local anaesthetic toxicity
Abstract
Local anaesthetic drugs are widely used for the provision of regional ana-
esthesia and analgesia. When used properly, they are safe and effective and
have only few side effects. However, in case of an accidental intravascular
injection or an injection of excessive dose, they can be toxic and neurologic
and cardiovascular symptoms may occur. Systemic toxicity, although a rare
complication, can be life threatening and resistant to treatment. This re-
view offers a brief overview of the current understanding of the circum-
stances that cause systemic and cardiovascular toxicity in the daily clinical
practice and the management of clinical signs and symptoms.
INTRODUCTION
The use of regional anaesthesia, alone or as adjunct to general ana-esthesia, is at an all-time high. However, with the development of
the equipment, techniques and medication, we are witnessing a signifi-
cant increase in the use of regional anaesthesia. Although the benefits
of regional anaesthesia are well-known and include reduced side effects
and enhanced patient’s satisfaction, as the number of practitioners and
procedures increase, the number of complications and adverse outcome
rise as well. Complications of local anaesthesia may range from local-
ized reactions such as edema, urticaria and dermatitis to systemic ab-
sorption resulting in severe cardiovascular collapse and neurological
toxicity.
Local anaesthetic drugs are used widely for the provision of regional
anaesthesia and analgesia, and despite the remarkable efficacy, the risk
of systemic toxicity associated with these drugs has been a very impor-
tant problem since their introduction to clinical practice more than a
hundred years ago. While generally safe, they can be toxic if used in ex-
cessive doses or administered improperly. An unintentionally high local
anaesthetic plasma concentration which may be due to overdosing,
rapid absorption from the injection site, diminished tolerance, or from
unintentional intravascular injection may lead to a serious of progres-
sively worsening neurological and cardiac complications. Unexpected
local anaesthetic toxicity can also occur where the pharmacokinetics of
the drug are altered by co-morbidity such as cardiac, renal or hepatic
failure, alterations in plasma protein binding, or interactions with other
drugs. Systemic toxicity from local anaesthetics can be life threatening
and very often resistant to treatment.
The estimate of clinically important local anaesthetic toxicity is from
7.5 to 20 occurrences per 10,000 peripheral nerve blocks and approxi-
mately 4 occurrences per 10,000 epidurals (1). The most important goal
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Overview
treat toxicity once it has occurred. This review offers a
brief overview of the current understanding of the cir-
cumstances that cause systemic toxicity in the daily clini-
cal practice and the management of clinical signs and
symptoms.
Brief history of local anaesthetics
toxicity
The clinical phenomenon of local anaesthetic toxicity
has been known for more than a hundred years and had
several peaks including introduction of cocaine in 1884,
bupivacaine and etidocaine in the 1970s and after the in-
troduction of ropivacaine and levobupivacaine in the
1980s.
Shortly after the introduction of cocaine as a topical
anaesthetic into clinical practice, local anaesthetic sys-
temic toxicity has been recognized and reported. Be-
tween 1884 and 1891, 200 cases of systemic intoxication
and 13 deaths attributed to the cocaine were recorded (2).
Wider recognition that LA toxicity could have lethal con-
sequences should have followed reports of 7 deaths in
nearly 40,000 patients with the use of topical cocaine or
tetracaine anaesthesia to facilitate tracheobronchoscopy
or esophagogastroscopy (3). Increasing evidence of toxic-
ity directly attributable to local anaesthetic use led the
American Medical Association (AMA) in the early 1920s
to establish the Committee for the Study of Toxic Effects
of Local Anaesthetics (4). The need for a local anaes-
thetic with reduced toxicity led to the development of
safer local anaesthetics, but despite of their introduction,
serious morbidity and mortality continued. For this rea-
son, interest in treatment and prevention of toxicity did
not stop until nowadays. In the 1990s, literature describ-
ing animal studies and reported cases in humans has
shown that lipid emulsions might be effective as an anti-
dote in the reversal of local anaesthetic toxicity. Research
is currently ongoing to refine issues related to lipid emul-
sion therapy for severe toxicity and its prodromes (5).
Until 2005 there was no widely agreed approach to the
management of LA toxicity. However, The Association
of Anaesthetists of Great Britain and Ireland (AAGBI)
published in 2007 the first set of standardized guidelines
for severe LA toxicity (6). In 2008, the American Society
of Critical Care Anaesthesiologists and the American So-
ciety of esiologists Committee on Critical Care Medicine
(7) as well as the Resuscitation Council of the United
Kingdom (8) also published protocols for the treatment
of local anaesthetic systemic toxicity (LAST). In 2010,
the American Society of Regional Anaesthesia and Pain
Medicine published its practice advisory on LAST (9).
Local anaesthetic systemic toxicity
Local anaesthetic systemic toxicity is a rare but poten-
tially fatal complication of regional anaesthesia. It may
occur as a consequence of unwanted intravascular injec-
tion, or after the administration of an excessive dose of
these drugs. Systemic toxicity of local anaesthetic affects
the central nervous system (CNS) and then the cardio-
vascular system (CVS). The central nervous system is
more sensitive to local anaesthetic toxicity than the car-
diovascular system (10).The dose and blood level of local
anaesthetic that produces CNS toxicity is lower than the
dose that causes circulatory collapse. Therefore CNS
manifestations tend to occur earlier. Although local ana-
esthetic cardiovascular toxicity occurs less frequently
than CNS toxicity, it is more serious and more difficult to
treat. Toxicity may be potentiated in patients with renal,
hepatic or cardiac failure, respiratory acidosis, during
pregnancy, at the extremes of age or in hypoxic patients.
Several factors such as physiochemical properties, rate
and route of administration of the LA also influence the
acute systemic toxicity.
The onset of toxicity is the direct result of the rate and
route of drug administration. Inadvertent, direct intrave-
nous injection of an excessive dose can cause rapid and
intense level of central nervous and cardiovascular sys-
tem toxicity. Tissue vascularity is another important con-
sideration. Highly vascular injection sites, such as the
pleura, the bronchial mucosa and sublingual regions,
have a higher correlation to an increased incidence of lo-
cal anaesthetic toxicity than do less vascular areas. The
uptake of local anaesthetic from greatest to least is as fol-
lows: Blood/tracheal > Intercostal > Caudal/paracer-
vical > Epidural > Perivascular brachial plexus > Sci-
atic > Subcutaneous – BICEPSS.
The central toxic response is related specifically to
plasma concentrations of local anaesthetic in the CNS
and their effect on the complex interplay between excit-
atory and inhibitory pathways (11). CNS toxicity is bi-
phasic (Table 1). Initial symptoms are due to CNS exci-
tation manifesting as feeling of lightheadedness, shiver-
ing, confusion, abnormal taste, dizziness, and tinnitus,
visual and auditory disturbances followed by tonic-clo-
nic convulsions. Subsequent manifestations include CNS
depression with a cessation of convulsions and onset of
unconsciousness, coma, respiratory depression, and re-
spiratory arrest. This biphasic effect occurs because local
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TABLE 1
Symptoms of systemic toxicity.






















anaesthetics first block sodium channels in the inhibi-
tory neurons allowing the excitatory neurons to act un-
opposed and creating an excitatory state. Consequently,
both inhibitory and excitatory pathways are blocked re-
sulting in the global CNS inhibition. There is a correla-
tion between local anaesthetic potency and the dosage
required to produce CNS toxicity (12). The convulsive
dose of long acting LAs are up to 4 times more toxic than
lidocaine (13). In dogs the relative CNS toxicity of bu-
pivacaine, etidocaine, and lidocaine is 4:2:1. This is simi-
lar to their relative local anaesthetic potencies (14). Intra-
venous infusion studies in human volunteers also show a
similar relationship between the intrinsic anaesthetic po-
tency and the dosage that causes CNS symptoms (15).
The rate of injection affects the maximum concentra-
tion of LA in the serum and time to peak levels. For ex-
ample, when etidocaine is infused into human volun-
teers at the rate 10 mg/mL, (mean dose of 236 mg)
symptoms of CNS occur when the blood levels reaches
3,0 mg/mL. Increasing the infusion rate to 20 mg/mL
CNS symptoms occur when the blood concentration
reaches only 2.0 mg/mL (mean dose 161 mg) (Figure 1)
Therefore, subjects could tolerate twice the dose of etido-
caine at a lower infusion rate of 10 mg/min (16).
The acid-base status of the patient can also influence
the central nervous system toxicity. In cats, with increas-
ing arterial PCO2, the lower doses of LA were required to
produce convulsions. Increasing the PCO2 from 25 to 40
mmHg to 65 to 80 mmHg decreased the dose required to
produce convulsions for different local anaesthetics by
approximately 50 % (12).
It can also be considered that, in terms of CNS toxic-
ity, a decrease in pH is probably more important than a
change in PaCO2. Respiratory acidosis decreases the thre-
shold for occurrence of seizures. Acidosis and hyper-
carbia may alter the convulsive threshold in several ways.
CO2 increases cerebral blood flow so more local anaes-
thetic is delivered to the brain and has itself an excitatory
effect on subcortical brain structure. Additionally, hyper-
carbia and/or acidosis also decrease the plasma protein
binding of local anaesthetic agents thus making more
drugs available in brain. Seizures produce hypoventila-
tion and a combined respiratory and metabolic acidosis,
which further exacerbates the CNS toxicity.
The cardiovascular system (CVS) is generally more
resistant to local anaesthetic toxicity than the CNS. Car-
diovascular toxicity usually occurs at doses and blood
concentrations higher than those required to produce
CNS toxicity. A study by Lin et al. demonstrated that in
dogs there was a three to five fold difference between
blood concentrations of LA required to produce cardi-
circulatory collapse and those to produce convulsion
(14).
Relative potency for CV toxicity also seems to follow
the relative anaesthetic potency. More potent agents,
such as bupivacaine, etidocaine, and tetracaine have been
shown to be more cardiotoxic than less potent agents
such as lidocaine, mepivacaine, or prilocaine (17).
CV toxicity is also biphasic (Table 1). The first signs of
cardiac toxicity are related to the CNS excitatory phase
with activation of the sympathetic nervous system which
leads to tachycardia and hypertension and can mask di-
rect myocardial depression. However with increasing
plasma concentration of LA, this phase is followed by
bradycardia, arrhythmia and profound cardiac depres-
sion, resulting in cardiovascular collapse (18, 19).
The mechanism of cardiovascular toxicity is based on
direct and indirect effect of LA on the myocardium and
on vascular smooth muscle, but is not fully elucidated
(20, 21). Direct effects on myocardium include negative
inotropy and conduction delay while the indirect effects
include effect on the cardiac centre in the middle brain
(22).
Calcium ion channel blockade is considered to be one
of the main mechanisms of LA induced cardiac depres-
sion and negative inotropy. Displacement of calcium
from cardiac muscle would result in a decrease in myo-
cardial contractility. Blockade of sodium ion channel
which reduces action potential duration and effective re-
fractory period, induces inhibition of cyclic adenosine
monophosphate (cAMP) and inhibition of carnitine trans-
porter system may also contribute to cardiac toxicity. LA
also increases PR interval and QRS complex duration re-
sulting in prolongation of conduction time. In the iso-
lated rabbit heart it has been shown that racemic bupi-
vacaine, levobupivacaine and ropivacaine induce an in-
crease in QRS duration in the ratio of 1:0.4:0.3 (23).
The direct peripheral vascular effects include a bipha-
sic response of vascular smooth muscles characterized by
initial vasoconstriction followed by vasodilatation. Pe-
ripheral vasodilatation worsens the hypotension.
Cardiotoxic effects of different local anaesthetics can
be compared using the CC/CNS ratio. This is the ratio of
the dosage required for cardiovascular collapse and dos-
age that will produce convulsion. The lower the ratio, the
more cardiotoxic the drug is. The cardiovascular to CNS
ratio for bupivacaine is 2.0, for lignocaine it is 7.1, for
ropivicaine it is 2.2, which indicates that the toxic effects
are more pronounced with bupivacaine. Ventricular arrhy-
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Figure 1. Effect of infusion rate on local anesthetic toxicity (Modified
to ref. 16).
thmias including fibrillation are more common with
bupivacaine and cardiac resuscitation is more difficult
after bupivacaine induced cardiovascular collapse. Bu-
pivacaine is more arrhythmogenic than lidocaine and
other LA. Bupivacaine blocks the SA node, prolongs the
P-R interval and induces more reentrant type of arrhy-
thmias. All this is due to the fact that bupivacaine is more
strongly bound to the receptor site within the sodium
channel compared to lidocaine, especially in cardiac mu-
scle (24). Cardiac toxicity of local anesthetic is more pro-
nounced in some conditions. Acidosis and hypoxia mar-
kedly potentiate the cardiotoxicity of bupivacaine. Preg-
nancy also may increase sensitivity to cardiotoxic effect of
bupivacaine more than ropivacaine and some other LA
(25). Physiological changes that occur during pregnancy
increase the risk of LA toxicity. A higher cardiac output
enhances blood perfusion to the site of LA injection and
leads to more rapid absorption. Progesterone may in-
crease neural sensitivity to neural blockade. Lower doses
of local anesthetic are needed per dermatomal segment
of epidural or spinal block. The plasma protein binding
of bupivacaine is reduced in pregnancy, which also may
increase the risk of toxicity.
Management of severe local
anaesthetic toxicity
In the patient with suspected local anaesthetic toxic-
ity, the first step is to ensure adequate ventilation and ox-
ygenation, since hypoxemia, hypercarbia and acidosis
enhance the toxicity. The second step is controlling the
seizure with the administration of small doses of benzo-
diazepines, followed by thiopental or propofol if seizures
persist. Convulsions are often followed by hypoxia and
hypercapnia, which additionally significantly increase
the risk of cardiac depression. The generally recommen-
ded doses to stop the seizure are 2–5 mg of midazolam,
50–100 mg of thiopental and 1mg/kg of propofol all
given intravenously. Benzodiazepines are the drug of
choice because of their minimal cardio-depressant ef-
fects. Clinicians should be aware that propofol and thio-
pental can cause significant hypotension or cardiac de-
pression that can further compromise the cardiovascular
status of the patient. In the case of cardiac arrest standard
basic life support (BLS) and advanced cardiac life sup-
port (ACLS) should be started.
As already mentioned, The Association of Anaesthe-
tists of Great Britain and Ireland (AAGBI) published the
first set of standardized guidelines for severe LA toxicity
(6). In the next three years, the American Society of Criti-
cal Care Anaesthesiologists, the American Society of Ana-
esthesiologists Committee on Critical Care Medicine (7),
the Resuscitation Council of the United Kingdom (8)
and the American Society of Regional Anaesthesia and
Pain Medicine also published protocols for the treatment
of local anaesthetic systemic toxicity (9). These guide-
lines highlighted the importance of oxygenation and
early cardiopulmonary resuscitation but also highlighted
the use of intravenous lipid emulsion (ILE) as a new po-
tential in the treatment of local anaesthetic toxicity. Wein-
berg et al. (26) reported the first use of lipid emulsion
therapy in animals. They demonstrated that pretreat-
ment or resuscitation with intravenous lipid emulsion
resulted in amelioration of bupivacaine cardiotoxicity in
rats. The same authors later confirmed these finding in
dogs (27). Rosenblatt et al. (28) and Litz et al. (29) re-
ported the first clinical application of such therapy. Their
patients had undergone an interscalene block with
bupivacaine and mepivacaine and an axillary block with
ropivacaine, respectively. When the patients were failing
to respond to routine cardiopulmonary resuscitation
(CPR) measures, lipid emulsion therapy was adminis-
trated. The use of this therapy led to the patients’ quick
reversal of cardiac arrhythmias and successful resuscita-
tion. Use of lipid emulsion as antidote in this clinical sit-
uation triggered number of subsequent reports describ-
ing the successful resuscitation of toxicity due to LAs.
The mechanism of action of lipid emulsions is not fully
established, but there are several possible mechanisms by
which they could act as an antidote for drug toxicity. The
»lipid sink« phenomenon is the most widely accepted
mechanism of action of ILE. Intravenous lipid emulsion
might acts as a circulating lipid sink, drawing LA out of
the plasma and binding it, so that no more free fraction
exists to bind to the receptors.
The second possible mechanism is reversal of mito-
chondrial fatty acid transport inhibition. It is known that
those local anaesthetics inhibit carnitine acylcarnitine trans-
locase (CACT), which is essential in transport of fatty ac-
ids across the inner mitochondrial membrane. Because
fatty acids are involved in 80% to 90% of cardiac adeno-
sine 5’-triphosphate (ATP) synthesis, inhibition of CACT
may contribute to cardiac toxicity (30). Lipid emulsion
could theoretically increase intracellular fatty acid con-
tent and therefore overcome this inhibition. The third
possible mechanism is that the intravenous lipid emul-
sion could have a direct inotropic effect by increasing
intramyocyte calcium concentration.
Although, initial recommendations suggested that li-
pid rescue be applied only after standard resuscitation
measures have failed, most recent recommendations sug-
gest that intralipid therapy should be considered at the
first signs of local anaesthetic induced cardiotoxicity.
The recommendation is to administer an initial in-
travenous bolus injection of 20% Intralipid at 1.5 mL/
kg over one minute followed by infusion of 0.25 mL/kg/
min. Cardiopulmonary resuscitation should be contin-
ued. If cardiovascular stability is not restored after 5
minutes the bolus should be repeated twice at 5 minute
intervals with doubled infusion rate to 0.5 mL/kg/min.
It is recommended that the infusion rate is continued
until an adequate stable circulation has been restored.
A maximum of three boluses can be given, and a cumu-
lative dose of 10 mL/kg should not be exceeded (Table
2). If all of this fails, cardiopulmonary bypass, if avail-
able, may be instituted until the local anaesthetic has
been metabolized.
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In the setting of anaesthetic toxicity, it is also impor-
tant to mention that the aforementioned 2010 ASRA
guidelines recommend the use of low dose epinephrine,
and avoiding vasopressin completely in the setting of
LAST. Although epinephrine is a first line drug for treat-
ing cardiac arrest, it has been shown to induce arrhy-
thmias and seizures at lower doses of bupivacaine. There
is laboratory evidence that epinephrine can impair resus-
citation from LAST and reduce the efficacy of lipid res-
cue. Hiller et al. (31) demonstrated that adding epineph-
rine to the lipid emulsion at doses above 10 mg/kg led to
considerable decline in all hemodynamic and metabolic
parameters. Weinberg et al. (32) and Di Gregorio et al.
(33) also showed that lipid emulsion therapy provides
superior hemodynamic and metabolic recovery from bu-
pivacaine-induced cardiac arrest than epinephrine and
vasopressin.
Prevention
Regional anaesthesia should always be prepared in
environment equipped to mange anaesthesia and car-
diac arrest (oxygen, monitoring of NIBP, SpO2 and
ETCO2, suction). Although new medication, equipment
and techniques may improve outcome when unintended
high blood levels of local anaesthetics occur, the primary
focus of daily practice should remain the prevention of
such events. As most systemic toxic reactions to local anaes-
thetics occur as a result of unintended intravascular in-
jection, it is important to take certain measures to prevent
the risk of such occurrences. There is no single clinical
measure that can prevent LAST. The first steps are to
limit effective doses, aspiration after positioning the nee-
dle and adding epinephrine to the LA as an indicator of
intravascular injection. The injection of relatively large
volume of LA should be done in increments, thus reduc-
ing the toxic doses if it is inadvertently injected intravas-
cularly (Table 2). In addition, complication such as intra-
vascular or intraneural injection can be avoided by using
ultrasound-guided regional anaesthesia. Compared with
alternative techniques ultrasound guidance is associated
with an increased success rate, reduced onset time, mod-
erately prolonged duration, reduced need for local anaes-
thetics and lower costs, and may also be considered to re-
duce the risk for complications, although there are no
randomized controlled studies to confirm or deny this
assertion (34).
Although the toxicity of local anaesthetic is indisput-
able and can be life-threatening, it should be emphasized
that this drugs are very safe. The safe and effective use of
local anaesthetics depends primarily on good clinical skills,
proper dosage, correct technique, adequate precautions
and readiness for emergencies. Numerous guidelines and
protocols for the management of local anaesthetic sys-
temic toxicity have been published in recent years. All cli-
nicians should be familiar, prior to use of local anaesthetics,
with these protocols and lipid emulsion must be avail-
able in all areas where regional anaesthesia is practiced.
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